發送短信 : Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

  _  _    __   __   __   __   _    _     ______  
 | \| ||  \ \\/ //  \ \\/ // | || | ||  /_   _// 
 |  ' ||   \ ` //    \   //  | || | ||  `-| |,-  
 | .  ||    | ||     / . \\  | \\_/ ||    | ||   
 |_|\_||    |_||    /_//\_\\  \____//     |_||   
 `-` -`     `-`'    `-`  --`   `---`      `-`'